An immunodominant SSX-2–derived epitope recognized by CD4⁺ T cells in association with HLA-DR
J. Clin. Invest. Maha Ayyoub, et al. 113:1225 doi:10.1172/JCI20667 [Go to this article.]

Figure 3
Determination of the minimal sequence optimally recognized by SSX-2–specific CD4⁺ T cells and assessment of cross-recognition of homologous peptides from other SSX antigens. (A and B) Synthetic peptides truncated at the N- or C- terminus of the SSX-2_37–58 sequence were used to determine the optimal length of the epitope recognized by SSX-2–specific CD4⁺ T cells. Peptide activity was calculated relative to that of SSX-2_37–58 in peptide-titration experiments. (C) Binding score and ranking of SSX-2_45–59–homologous peptides from other SSX antigens were calculated using the SYFPEITHI binding prediction program (http://www.syfpeithi.de). (D) Cross-recognition of 45–59 homologous peptides from SSX-1 and -5 by SSX-2–specific CD4⁺ T cells was assessed in peptide-titration experiments by ELISA measurement of IFN-γ secretion in the culture supernatant.